![Niklas Axelsson](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Niklas Axelsson
No más puestos en curso
Fortuna: 540 $ al 31/07/2026
Perfil
Mr. Niklas Axelsson was previously employed as a Chief Financial Officer by Diamyd Medical AB and a Chief Financial Officer by Sprint Bioscience AB. He received his undergraduate degree from Stockholm School of Economics.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 31/08/2025 | 5.000 ( 0 % ) | 540 $ | 31/07/2026 |
Antiguos cargos conocidos de Niklas Axelsson.
| Empresas | Cargo | Fin |
|---|---|---|
| DIAMYD MEDICAL AB | Director Financiero/CFO | 01/07/2026 |
| SPRINT BIOSCIENCE AB | Director Financiero/CFO | - |
Formación de Niklas Axelsson.
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
1
Relaciones de 1er grado
3
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 3 |
|---|---|
Stockholm School of Economics
 Stockholm School of Economics Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Sprint Bioscience AB
 Sprint Bioscience AB Pharmaceuticals: MajorHealth Technology Develops medicines in the field of cancer and metabolism | Health Technology |
Diamyd Medical AB
 Diamyd Medical AB Pharmaceuticals: MajorHealth Technology Develops precision medicine drugs for type 1 diabetes and other forms of autoimmune diabetes | Health Technology |
- Bolsa de valores
- Insiders
- Niklas Axelsson
